58 related articles for article (PubMed ID: 22019557)
1. RGD-based active targeting of novel polycation liposomes bearing siRNA for cancer treatment.
Yonenaga N; Kenjo E; Asai T; Tsuruta A; Shimizu K; Dewa T; Nango M; Oku N
J Control Release; 2012 Jun; 160(2):177-81. PubMed ID: 22019557
[TBL] [Abstract][Full Text] [Related]
2. Novel RGD-lipid conjugate-modified liposomes for enhancing siRNA delivery in human retinal pigment epithelial cells.
Chen CW; Lu DW; Yeh MK; Shiau CY; Chiang CH
Int J Nanomedicine; 2011; 6():2567-80. PubMed ID: 22128247
[TBL] [Abstract][Full Text] [Related]
3. Targeted gene silencing using RGD-labeled chitosan nanoparticles.
Han HD; Mangala LS; Lee JW; Shahzad MM; Kim HS; Shen D; Nam EJ; Mora EM; Stone RL; Lu C; Lee SJ; Roh JW; Nick AM; Lopez-Berestein G; Sood AK
Clin Cancer Res; 2010 Aug; 16(15):3910-22. PubMed ID: 20538762
[TBL] [Abstract][Full Text] [Related]
4. Uptake and transfection efficiency of PEGylated cationic liposome-DNA complexes with and without RGD-tagging.
Majzoub RN; Chan CL; Ewert KK; Silva BF; Liang KS; Jacovetty EL; Carragher B; Potter CS; Safinya CR
Biomaterials; 2014 Jun; 35(18):4996-5005. PubMed ID: 24661552
[TBL] [Abstract][Full Text] [Related]
5. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle.
Schiffelers RM; Ansari A; Xu J; Zhou Q; Tang Q; Storm G; Molema G; Lu PY; Scaria PV; Woodle MC
Nucleic Acids Res; 2004 Nov; 32(19):e149. PubMed ID: 15520458
[TBL] [Abstract][Full Text] [Related]
6. iRGD-guided Tumor-penetrating Nanocomplexes for Therapeutic siRNA Delivery to Pancreatic Cancer.
Lo JH; Hao L; Muzumdar MD; Raghavan S; Kwon EJ; Pulver EM; Hsu F; Aguirre AJ; Wolpin BM; Fuchs CS; Hahn WC; Jacks T; Bhatia SN
Mol Cancer Ther; 2018 Nov; 17(11):2377-2388. PubMed ID: 30097486
[TBL] [Abstract][Full Text] [Related]
7. Regulating intracellular fate of siRNA by endoplasmic reticulum membrane-decorated hybrid nanoplexes.
Qiu C; Han HH; Sun J; Zhang HT; Wei W; Cui SH; Chen X; Wang JC; Zhang Q
Nat Commun; 2019 Jun; 10(1):2702. PubMed ID: 31221991
[TBL] [Abstract][Full Text] [Related]
8. Plasmid DNA ionisable lipid nanoparticles as non-inert carriers and potent immune activators for cancer immunotherapy.
Qin Y; Rouatbi N; Wang JT; Baker R; Spicer J; Walters AA; Al-Jamal KT
J Control Release; 2024 May; 369():251-265. PubMed ID: 38493950
[TBL] [Abstract][Full Text] [Related]
9. Targeting HPV-infected cervical cancer cells with PEGylated liposomes encapsulating siRNA and the role of siRNA complexation with polyethylenimine.
Levine RM; Dinh CV; Harris MA; Kokkoli E
Bioeng Transl Med; 2016 Jun; 1(2):168-180. PubMed ID: 29313012
[TBL] [Abstract][Full Text] [Related]
10. A novel method for conjugating the terminal amine of peptide ligands to cholesterol: synthesis iRGD-cholesterol.
Fete MG; Betker JL; Shoemaker RK; Anchordoquy TJ
Ther Deliv; 2019 Jan; 10(1):11-20. PubMed ID: 30730822
[TBL] [Abstract][Full Text] [Related]
11. A Robust Nanoparticle Platform for RNA Interference in Macrophages to Suppress Tumor Cell Migration.
Liang S; Zheng J; Wu W; Li Q; Saw PE; Chen J; Xu X; Yao H; Yao Y
Front Pharmacol; 2018; 9():1465. PubMed ID: 30618757
[TBL] [Abstract][Full Text] [Related]
12. A landscape of recent advances in lipid nanoparticles and their translational potential for the treatment of solid tumors.
Paun RA; Jurchuk S; Tabrizian M
Bioeng Transl Med; 2024 Mar; 9(2):e10601. PubMed ID: 38435821
[TBL] [Abstract][Full Text] [Related]
13. Nanoparticles for vaccine and gene therapy: Overcoming the barriers to nucleic acid delivery.
Mollé LM; Smyth CH; Yuen D; Johnston APR
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2022 Nov; 14(6):e1809. PubMed ID: 36416028
[TBL] [Abstract][Full Text] [Related]
14. Application and Utility of Liposomal Neuroprotective Agents and Biomimetic Nanoparticles for the Treatment of Ischemic Stroke.
Fukuta T; Oku N; Kogure K
Pharmaceutics; 2022 Feb; 14(2):. PubMed ID: 35214092
[TBL] [Abstract][Full Text] [Related]
15. Lipophilic Polyamines as Promising Components of Liposomal Gene Delivery Systems.
Puchkov PA; Maslov MA
Pharmaceutics; 2021 Jun; 13(6):. PubMed ID: 34205825
[TBL] [Abstract][Full Text] [Related]
16. Viral Mimicry as a Design Template for Nucleic Acid Nanocarriers.
de la Fuente IF; Sawant SS; Tolentino MQ; Corrigan PM; Rouge JL
Front Chem; 2021; 9():613209. PubMed ID: 33777893
[TBL] [Abstract][Full Text] [Related]
17. Cyclic RGD-conjugated Pluronic
Lim C; Moon J; Sim T; Hoang NH; Won WR; Lee ES; Youn YS; Choi HG; Oh K; Oh KT
Int J Nanomedicine; 2018; 13():4627-4639. PubMed ID: 30127610
[TBL] [Abstract][Full Text] [Related]
18. Engineering liposomal nanoparticles for targeted gene therapy.
Zylberberg C; Gaskill K; Pasley S; Matosevic S
Gene Ther; 2017 Aug; 24(8):441-452. PubMed ID: 28504657
[TBL] [Abstract][Full Text] [Related]
19. ICAM-1-Targeted, Lcn2 siRNA-Encapsulating Liposomes are Potent Anti-angiogenic Agents for Triple Negative Breast Cancer.
Guo P; Yang J; Jia D; Moses MA; Auguste DT
Theranostics; 2016; 6(1):1-13. PubMed ID: 26722369
[TBL] [Abstract][Full Text] [Related]
20. Effect of surface properties on liposomal siRNA delivery.
Xia Y; Tian J; Chen X
Biomaterials; 2016 Feb; 79():56-68. PubMed ID: 26695117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
